Jacqualyn Fouse - Feb 14, 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Chief Executive Officer, Director
Signature
/s/ William Cook, as Attorney-in-fact for Jacqualyn Fouse
Stock symbol
AGIO
Transactions as of
Feb 14, 2022
Transactions value $
-$106,903
Form type
4
Date filed
2/16/2022, 04:01 PM
Previous filing
Jan 4, 2022
Next filing
Feb 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $0 +11.3K +19.42% $0.00 69.7K Feb 14, 2022 Direct F1
transaction AGIO Common stock Tax liability -$107K -3.51K -5.03% $30.50 66.2K Feb 14, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Restricted stock units Options Exercise $0 -11.3K -50% $0.00 11.3K Feb 14, 2022 Common stock 11.3K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2 The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.